title: Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment.
authors.forename: Abraham C J
authors.initials: AC
authors.lastname: Stork
authors.forename: Nicolette C
authors.initials: NC
authors.lastname: Notermans
authors.forename: Alexander F J E
authors.initials: AF
authors.lastname: Vrancken
authors.forename: David R
authors.initials: DR
authors.lastname: Cornblath
authors.forename: W-Ludo
authors.initials: WL
authors.lastname: van der Pol
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects*; D018450:Disease Progression; D004594:Electrophysiology; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000276:immunology*; D007155:Immunologic Factors / Q000009:adverse effects*; D008297:Male; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D010265:Paraproteinemias; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D007155:Immunologic Factors; D018992:Myelin-Associated Glycoprotein; D000069283:Rituximab